Puma Biotechnology, Inc.
PBYIHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePuma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company carries a $568.9M market cap, placing it firmly in the small-cap category. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Market Cap
$568.9M
Beta
1.21
P/E (TTM)
21.61
P/E (Fwd)
31.49
EPS (TTM)
$0.51
EPS (Fwd)
$0.35
ROE
22.0%
ROA
9.8%
Cash
$93.9M
Total Debt
$4.8M
Free CF
$32.5M
52W Change
109.1%
Annual Financials
Cash vs Debt
Where PBYI stands vs its 150-day and 200-day moving averages
As of the October 14, 2026 close, PBYI finished 26.66% above its 150-day moving average ($7.99) and 32.81% above its 200-day moving average ($7.62). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PBYI overbought or oversold?
At the October 14, 2026 close, PBYI's RSI(14) was 66.5, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Puma Biotechnology, Inc. holds $93.9M in cash against $4.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $32.5M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 22.0% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 9.8% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $228.0M (2022) to $228.4M (2025).
With cash comfortably exceeding debt, PBYI has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing PBYI's risk profile alongside its fundamentals and technical indicators provides a more complete picture.